Chdi Foundation, Inc.

Ucb Pharma, S.a.

Ucb Biopharma Sprl

Gilles Raphy

Alan Findlay Haughan

Roland W Bürli

Celia Dominguez

Andrew Sharpe

Julien Alistair Brown

Christopher A Luckhurst

Ignacio Muñoz-Sanjuán

Daniel Rees Allen

Michael Wall

Grant Wishart

Perla Breccia

Elizabeth Anne Saville-Stones

Rebecca E Jarvis

Samantha J Hughes

Stephen David Penrose

Mizio Matteucci

Andrew Pate Owens

Andrew J Stott

Huw David Vater

Beth Thomas

Vahri Beaumont

Michel C Maillard

David John Nash

Jonathan David MacDonald

Huw D Vater

Roland W BÛRLI

Ignacio Mun Oz-Sanjuan

Roland BÜRLI

Jonathan David Macdonald

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. 

Histone deacetylase inhibitors and compositions and methods of use thereof

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. 

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein. 

A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors

A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Triazine derivatives as kinase inhibitors

A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Quinoline derivatives as kinase inhibitors

A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Growing community of inventors

Saffron Walden, United Kingdom

Gilles Raphy